Sciele rated at sector perform by RBC

RBC Capital Markets analyst Ken Trbovich maintained Sciele Pharma, Inc. at sector perform, above average risk with a $23 price target, as the company reported net revenue of $72 million compared to RBC's estimate of $69 million and Street consensus of $68 million. Sales of the company's women's health and other products were $4.5 million lower than expected, however, the cardiology product group exceeded the analyst's expectations by $7.8 million. Management raised the 2006 revenue guidance range by $5 million to $275 million to $285 million. Shares of the Atlanta-based pharmaceutical company were down $1.71 cents, or 7.94%, at $19.83 on volume of 1,646,971 shares versus the three-month running average of 600,236 shares. (Nasdaq: SCRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.